FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 150 filers reported holding FATE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,187,000 | -16.4% | 52,950 | -7.6% | 0.01% | -21.4% |
Q2 2022 | $1,420,000 | -86.8% | 57,320 | -56.1% | 0.01% | -86.7% |
Q1 2021 | $10,775,000 | -4.7% | 130,688 | +5.1% | 0.10% | -17.3% |
Q4 2020 | $11,309,000 | +155.5% | 124,368 | +12.3% | 0.13% | +95.4% |
Q3 2020 | $4,427,000 | +21.8% | 110,747 | +4.5% | 0.06% | +32.7% |
Q2 2020 | $3,636,000 | +19.1% | 105,979 | -22.9% | 0.05% | +4.3% |
Q1 2020 | $3,052,000 | +2.5% | 137,433 | -9.7% | 0.05% | +104.3% |
Q4 2019 | $2,978,000 | +47.1% | 152,157 | +16.7% | 0.02% | +43.8% |
Q3 2019 | $2,025,000 | -26.9% | 130,386 | -4.4% | 0.02% | -23.8% |
Q2 2019 | $2,770,000 | +1.2% | 136,434 | -12.5% | 0.02% | +10.5% |
Q1 2019 | $2,738,000 | +43.1% | 155,838 | +4.5% | 0.02% | +26.7% |
Q4 2018 | $1,913,000 | +24.2% | 149,103 | +57.7% | 0.02% | +50.0% |
Q3 2018 | $1,540,000 | +77.0% | 94,532 | +23.2% | 0.01% | +66.7% |
Q2 2018 | $870,000 | – | 76,714 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |